Diffusion-weighted imaging and the Alberta Stroke Program Early CT Score (DWI-ASPECTS)-guided intra-arterial thrombectomy beyond 6 hours: feasibility, substantial efficacy, and acceptable safety

弥散加权成像和阿尔伯塔卒中项目早期CT评分(DWI-ASPECTS)指导的动脉内血栓切除术在发病6小时后的应用:可行性、显著疗效和可接受的安全性

阅读:1

Abstract

OBJECTIVES: To assess the safety and efficacy of intra-arterial thrombectomy for patients with acute ischemic stroke due to large vessel occlusion (LVO) treated beyond the traditional 6-hour window, using diffusion-weighted imaging and the Alberta Stroke Program Early CT Score (DWI-ASPECTS) for patient selection. METHODS: A retrospective study was conducted at Hebei General Hospital, involving 263 acute stroke patients treated between November 2022 and August 2024. Patients were categorized into two cohorts based on treatment timing: within 6 hours (n = 156) and beyond 6 hours (n = 107). Outcomes included the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS), degree of vascular recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] scale), coagulation parameters, and adverse event rates as safety measures. RESULTS: Demographics and baseline conditions were comparable across groups. The beyond-6-hour group showed prolonged time from symptom onset to intervention, with slightly higher mRS and NIHSS scores at discharge and 90 days, indicating poorer functional and neurological outcomes (P < 0.05 for both). The beyond-6-hour group had a significantly lower vascular recanalization rate (mTICI ≥ 2b: 84.11%) compared to the within-6-hour group (93.59%, P = 0.013). However, the overall safety profile was similar, with no significant differences in adverse event rates. CONCLUSION: Intra-arterial thrombectomy beyond the standard 6-hour window was feasible, showing substantial efficacy and an acceptable safety profile when guided by DWI-ASPECTS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。